DCM
RIGL icon

DAFNA Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

DAFNA Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-39,007
Closed -$441K – 92
2022
Q2 		$441K Sell
39,007
-50,603
-56% -$1.02M 0.12% 77
2022
Q1 		$2.68M Buy
89,610
+1,710
+2% +$46.3K 0.7% 39
2021
Q4 		$2.33M Buy
87,900
+7,000
+9% +$211K 0.59% 39
2021
Q3 		$2.94M Buy
80,900
+56,500
+232% +$2.22M 0.78% 32
2021
Q2 		$1.06M Sell
24,400
-3,150
-11% -$119K 0.22% 70
2021
Q1 		$942K Buy
+27,550
New +$1.09M 0.22% 73
2020
Q3 		– Sell
-15,770
Closed -$289K – 86
2020
Q2 		$289K Hold
15,770
– – 0.08% 82
2020
Q1 		$246K Hold
15,770
– – 0.1% 75
2019
Q4 		$337K Hold
15,770
– – 0.12% 75
2019
Q3 		$295K Buy
15,770
+2,010
+15% +$41.5K 0.11% 78
2019
Q2 		$359K Hold
13,760
– – 0.13% 74
2019
Q1 		$354K Hold
13,760
– – 0.15% 69
2018
Q4 		$316K Hold
13,760
– – 0.16% 70
2018
Q3 		$442K Hold
13,760
– – 0.18% 59
2018
Q2 		$389K Sell
13,760
-76,433
-85% -$2.72M 0.18% 63
2018
Q1 		$3.19M Sell
90,193
-8,155
-8% -$326K 1.55% 24
2017
Q4 		$3.82M Buy
98,348
+54,000
+122% +$2.06M 2.06% 17
2017
Q3 		$1.13M Hold
44,348
– – 0.7% 43
2017
Q2 		$1.21M Sell
44,348
-3,000
-6% -$82.1K 0.86% 38
2017
Q1 		$1.57M Buy
+47,348
New +$1.21M 1.33% 28
2016
Q4 		– Sell
-34,000
Closed -$1.25M – 73
2016
Q3 		$1.25M Sell
34,000
-150,709
-82% -$4.32M 0.87% 38
2016
Q2 		$4.12M Sell
184,709
-2,940
-2% -$73.1K 3.26% 7
2016
Q1 		$3.9M Buy
187,649
+76,675
+69% +$1.89M 3.37% 5
2015
Q4 		$3.36M Hold
110,974
– – 3% 9
2015
Q3 		$2.74M Hold
110,974
– – 2.72% 10
2015
Q2 		$3.56M Hold
110,974
– – 3.01% 5
2015
Q1 		$3.96M Buy
110,974
+36,067
+48% +$989K 3.04% 7
2014
Q4 		$1.7M Buy
+74,907
New +$1.51M 1.34% 21

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DAFNA Capital Management's RIGL Position: Q3 2022 in Review

DAFNA Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 39,007 shares — an estimated $441K sold.

DAFNA Capital Management first reported a position in RIGL in Q4 2014 and held it in 28 quarters. The position peaked at $4.12M in Q2 2016. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.

  • DAFNA Capital Management reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • DAFNA Capital Management sold 39,007 Rigel Pharmaceuticals shares in Q3 2022, an estimated $441K.
  • DAFNA Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2014 and held it in 28 quarters.
  • DAFNA Capital Management's Rigel Pharmaceuticals position peaked at $4.12M in Q2 2016.
  • 138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.

Based on DAFNA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.